Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) is expected to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($1.02) per share for the quarter.

Corbus Pharmaceuticals Stock Down 7.8 %

Shares of CRBP opened at $6.96 on Tuesday. Corbus Pharmaceuticals has a fifty-two week low of $6.78 and a fifty-two week high of $61.90. The firm’s 50 day moving average price is $10.47 and its 200 day moving average price is $21.71. The company has a market cap of $84.77 million, a P/E ratio of -1.48 and a beta of 2.63.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CRBP shares. William Blair started coverage on shares of Corbus Pharmaceuticals in a research note on Friday. They set an “outperform” rating on the stock. Piper Sandler started coverage on shares of Corbus Pharmaceuticals in a research note on Monday, December 2nd. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Corbus Pharmaceuticals in a research note on Tuesday, February 18th. StockNews.com raised shares of Corbus Pharmaceuticals to a “sell” rating in a research report on Monday, January 13th. Finally, Wedbush reissued an “outperform” rating and issued a $51.00 price objective on shares of Corbus Pharmaceuticals in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $61.38.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.